Evidence map›Paper›PMID 37560206›Full record

ArticleAmerican journal of translational research2023

Computational identification of novel signature of T2DM-induced nephropathy and therapeutic bioactive compounds from

Bashir Lawal, Yu-Cheng Kuo, Sunday Amos Onikanni, Yi-Fong Chen, Tawakaltu Abdulrasheed-Adeleke, Adewale Oluwaseun Fadaka, Janet O Olugbodi, Halimat Yusuf Lukman, Femi Olawale, Mohamed H Mahmoud and 3 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Substrate Specificity and Immunological Implications ofJournal of microbiology and biotechnology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Molecules (Basel, Switzerland) · 2024
    Article
  6. Frontiers in chemistry · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bashir LawalUPMC Hillman Cancer Center, University of Pittsburgh Pittsburgh, PA, USA.
Yu-Cheng KuoDepartment of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University Taipei 11031, Taiwan.
Sunday Amos OnikanniDepartment of Chemical Sciences, Biochemistry Unit, Afe-Babalola University Ado-Ekiti, Ekiti State, Nigeria.
Yi-Fong ChenDivision of Medicinal Products, Taiwan Food and Drug Administration, Ministry of Health and Welfare No.161-2, Kunyang St., Nangang Dist., Taipei City 115209, Taiwan.
Tawakaltu Abdulrasheed-AdelekeDepartment of Biochemistry, Federal University of Technology P.M.B. 65, Minna 920001, Niger State, Nigeria.
Adewale Oluwaseun FadakaDepartment of Science and Innovation (DSI)/Mintek Nanotechnology Innovation Centre (NIC) Biolabels Research Node, Department of Biotechnology, University of the Western Cape Bellville 7535, South Africa.
Janet O OlugbodiNoble Life Sciences Inc. MD, USA.
Halimat Yusuf LukmanDepartment of Chemical Sciences, Biochemistry Unit, College of Natural and Applied Sciences, Summit University Offa, PMB 4412, Nigeria.
Femi OlawaleDepartment of Biochemistry, School of Life Science, University of KwaZulu Natal Durban, South Africa.
Mohamed H MahmoudDepartment of Biochemistry, College of Science, King Saud University Riyadh, Saudi Arabia.
Gaber El-Saber BatihaDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University Damanhour 22511, AlBeheira, Egypt.
Alexander Th WuTMU Research Center of Cancer Translational Medicine, Taipei Medical University Taipei 11031, Taiwan.
Hsu-Shan HuangPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, and Academia Sinica Taipei 11031, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDiabetic nephropathy (DN) is one of the most prevalent secondary complications associated with diabetes mellitus. Decades of research have implicated multiple pathways in the etiology and pathophysiology of diabetic nephropathy. There has been no reliable predictive biomarkers for the onset or progression of DN and no successful treatments are available.

methodsIn the present study, we explored the datasets of RNA sequencing data from patients with Type II diabetes mellitus (T2DM)-induced nephropathy to identify a novel gene signature. We explored the target bioactive compounds identified from

resultsOur analysis identified lymphotoxin beta (LTB), SRY-box transcription factor 4 (SOX4), SOX9, and WAP four-disulfide core domain protein 2 (WFDC2) as novel signatures of T2DM-induced nephropathy. Additional analysis revealed the pathological involvement of the signature in cell-cell adhesion, immune, and inflammatory responses during diabetic nephropathy. Molecular docking and dynamic simulation at 100 ns conducted studies revealed that among the three compounds, Terpinen-4-ol exhibited higher binding efficacies (binding energies (ΔG) = -3.9~5.5 kcal/mol) against the targets. The targets, SOX4, and SOX9 demonstrated higher druggability towards the three compounds. WFDC2 was the least attractive target for the compounds.

conclusionThe present study was relevant in the diagnosis, prognosis, and treatment follow up of patients with diabetes induced nephropathy. The study provided an insight into the therapeutic application of the bioactive principles from

Indexed as

Azanza garckeanabiochemical parameterdyslipidemiahepatopathynephropathy

Identifiers

PMID37560206
PMCPMC10408496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.